Roche (ROG) Goldman Sachs Conference presentation summary

Market trends and industry landscape

• Earlier diagnosis enables earlier treatment, especially in cancer detection.

• Novel diagnostics and treatments are emerging for diseases lacking interventions, such as Alzheimer's.

• Decentralization of care is increasing, with testing moving closer to patients.

• Digital healthcare is gaining importance, with new entrants and continuous patient monitoring becoming standard.

• Lab consolidation continues amid staffing shortages.

Strategic vision and goals

• Aims to maintain and expand leadership in clinical laboratories.

• Investing to become a leader in decentralized testing and disease management.

• Focuses on delivering integrated testing solutions and enabling confident healthcare decisions.

• Differentiates through comprehensive solutions for high-burden disease areas.

• Seeks to improve care along patient journeys and deliver medical value.

Product and innovation pipeline

• Diverse portfolio spans core lab, molecular lab, pathology, and near-patient care.

• Pipeline includes ~130 new assays over three years, targeting oncology, neurology, infectious, and cardiometabolic diseases.

• Launching cobas® 6800/8800 v2.0 for higher throughput and flexibility in PCR testing.

• Introducing cobas® Mass Spectrometry, aiming for 25% market share by 2031.

• Acquired LumiraDx, a multi-modal point-of-care platform for decentralized settings.